Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:00 pm Sale |
2022-12-31 | 13G | Surrozen, Inc. SRZN |
Baker Bros. Advisors LP | 55,556 2.300% |
-166,667 (-75.00%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | HOOKIPA Pharma Inc. HOOK |
Baker Bros. Advisors LP | 347,554 6.600% |
347,554 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Opthea Limited OPT |
Baker Bros. Advisors LP | 31,627,844 6.800% |
5,200,323 (+19.68%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA |
Baker Bros. Advisors LP | 180,913 9.990% |
180,913 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | 2seventy bio, Inc. TSVT |
Baker Bros. Advisors LP | 2,062,744 5.400% |
2,062,744 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Verastem, Inc. VSTM |
Baker Bros. Advisors LP | 2,249,075 13.500% |
458,106 (+25.58%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
Baker Bros. Advisors LP | 19,184,794 9.950% |
720,050 (+3.90%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Zymeworks Inc. ZYME |
Baker Bros. Advisors LP | 3,814,196 5.900% |
3,814,196 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Cerus Corporation CERS |
Baker Bros. Advisors LP | 16,087,422 9.100% |
2,354,363 (+17.14%) |
Filing History |
| 2023-02-14 4:00 pm Sale |
2022-12-31 | 13G | Merus N.V. MRUS |
Baker Bros. Advisors LP | 0 0.000% |
-2,037,469 (Position Closed) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Mereo BioPharma Group plc MREO |
Baker Bros. Advisors LP | 69,359,359 9.990% |
4,441,758 (+6.84%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Achilles Therapeutics plc ACHL |
Baker Bros. Advisors LP | 4,207,733 9.900% |
168,253 (+4.17%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Baker Bros. Advisors LP | 255,361 9.900% |
53,581 (+26.55%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Ascendis Pharma A/S ASND |
Baker Bros. Advisors LP | 4,954,855 8.700% |
413,251 (+9.10%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Baker Bros. Advisors LP | 1,976,868 8.000% |
145,079 (+7.92%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Biomea Fusion, Inc. BMEA |
Baker Bros. Advisors LP | 2,104,559 7.200% |
2,104,559 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Cabaletta Bio, Inc. CABA |
Baker Bros. Advisors LP | 1,344,000 5.200% |
1,344,000 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | CYTEIR THERAPEUTICS INC CYTT |
Baker Bros. Advisors LP | 2,492,118 7.000% |
2,492,118 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Immatics N.V. IMTX |
Baker Bros. Advisors LP | 5,187,081 6.800% |
763,350 (+17.26%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Replimune Group, Inc. REPL |
Baker Bros. Advisors LP | 5,768,227 9.990% |
5,768,227 (New Position) |
Filing History |